Analyst Price Targets — DNLI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 10:08 pm | Andrew Tsai | Jefferies | $40.00 | $21.00 | StreetInsider | Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) |
| January 8, 2026 12:43 pm | Sean Laaman | Morgan Stanley | $40.00 | $16.95 | TheFly | Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley |
| January 7, 2026 5:41 am | Michael Yee | UBS | $25.00 | $17.21 | StreetInsider | UBS Assumes Denali Therapeutics Inc. (DNLI) at Buy |
| December 11, 2025 1:30 pm | Laura Chico | Wedbush | $30.00 | $17.61 | TheFly | Denali Therapeutics price target lowered to $30 from $31 at Wedbush |
| December 5, 2025 12:44 pm | Laura Chico | Wedbush | $31.00 | $20.11 | TheFly | Denali Therapeutics price target raised to $31 from $30 at Wedbush |
| November 17, 2025 2:28 pm | Paul Mattels | Stifel Nicolaus | $37.00 | $17.67 | StreetInsider | Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) |
| January 7, 2025 12:22 pm | Thomas Shrader | BTIG | $32.00 | $21.18 | TheFly | Denali Therapeutics price target lowered to $32 from $35 at BTIG |
| November 1, 2024 9:46 am | Michael Yee | Jefferies | $45.00 | $27.05 | StreetInsider | Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies |
| October 14, 2024 6:04 am | Thomas Shrader | BTIG | $35.00 | $28.00 | StreetInsider | BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) |
| September 4, 2024 6:36 am | Tazeen Ahmad | Bank of America Securities | $29.00 | $25.12 | TheFly | Denali Therapeutics price target raised to $29 from $25 at BofA |
Latest News for DNLI
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights.
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines.
Aberdeen Group plc grew its position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 23.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,113,586 shares of the company's stock after purchasing an additional 210,835 shares
Shares of Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) have earned an average recommendation of "Buy" from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNLI.
U.S. House Trading
No House trades found for DNLI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.